HOME >> MEDICINE >> NEWS
New method of administering anti-cancer drug may be more effective, safer

CHAPEL HILL -- A novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion may be more effective and safer than the method currently used, new study findings indicate.

The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.

The findings were presented at the 2005 annual meeting of the American Society of Clinical Oncology, held May 13 through 17 in Orlando, Fla. The drug busulfan is used in leukemia patients to kill cancerous cells before bone-marrow transplant. Currently, it is administered in intermittent intravenous doses, typically via two-hour infusions of the drug every six hours. Previous studies have reported that frequent dose adjustments are needed to maintain the desired level of drug in patients and that metabolism of the drug varies from patient to patient.

"The new continuous-infusion method achieved more predictable levels of the drug than does the usual delivery method," said Dr. Thomas C. Shea, professor of medicine at UNC, director of the Bone Marrow Transplant Program at the UNC Health Care System and a member of the UNC Lineberger Comprehensive Cancer Center.

"In the relatively small number of patients tested with continuous infusion, there didn't appear to be a change in concentration or clearance of the drug during the 90-hour infusion period."

In 12 patients scheduled for bone marrow transplants, UNC researchers administered a single busulfan test dose of 0.8 mg/kg adjusted body weight over two hours. Blood concentrations of the drug were measured every two hours for eight hours following that test dose.

Then researchers administered busulfan by the novel method - patient
'"/>

Contact: Leslie H. Lang
llang@med.unc.edu
919-843-9687
University of North Carolina School of Medicine
18-May-2005


Page: 1 2

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. U of M researchers discover new method to combat HIV
3. New prevention, treatment methods for patients with painful bowel inflammation
4. Scientists develop method to track immune system enzyme in live animals
5. VA should revise its methods for evaluating and rating PTSD in veterans
6. Northwestern chemists develop new method for synthesizing anti-cancer flavonoids
7. Scientists develop method to remove prion infectivity from scrapie-infected blood
8. PhD researcher develops inexpensive, sustainable production method in just 2 years
9. Researchers develop novel method for treatment of sickle cell disease
10. Developing better methods of blinding doctors and patients in clinical trials
11. Cancer survival compromised by poor staging methods

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a ... Mahon was named a 2017 Top Patient Rated Henderson Dentist by Find ... that recognizes local physicians and dentists who have earned high ratings and superior patient ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Phoenix, announced today that it will soon begin franchising throughout the U.S. starting ... mission to help bring the practice of meditation mainstream. Current Meditation will be ...
(Date:2/23/2017)... , ... ... the perfect opportunity for the nation to come together to ... basketball bracket – with its favorite fruit – apples! To ... apple lovers to join the “Apple Madness” bracket tournament – ...
(Date:2/23/2017)... ... ... Curemark, LLC announced today that the Blüm Study, a Phase 3 clinical ... Autism, is now enrolling at three new sites. These new sites are in addition ... “There are currently no approved drugs that address the core symptoms of autism,” said ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Limited, ( ASX: ITD ), an innovative diversified healthcare company, is ... December 2016 compared with the previous corresponding period. A full "Results ... . Highlights Profit after ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up ... 11%) Profit before tax of $2.12m (Dec 2015: ...
(Date:2/23/2017)... Feb. 23, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Fibromyalgia Drugs ... benchmarks in the global Fibromyalgia market. The research answers ... drugs marketed for Fibromyalgia and their clinical attributes? How are they ...
(Date:2/23/2017)... Research and Markets has announced the addition ... Forecast to 2025" report to their offering. ... The Global Endoscopy Market is ... next decade to reach approximately $47.6 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Medicine Technology:
Cached News: